Drug
Zongertinib clinical trials
Also written Hernexeos® and BI 1810631.
Keep track of what changes. Save the zongertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Boehringer Ingelheim (13) · MedSIR (1)
Often tested with
Tested in the same studies.
Bosentan (1) · Rosuvastatin (1) · Metformin (1) · Furosemide (1) · Midazolam (1) · Omeprazole (1) · Repaglinide (1) · Carbamazepine (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses zongertinib is read from its arms, and is right about nine times in ten.
Testing it · 14
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsRecruitingPhase 2Boehringer IngelheimNCT06581432Written as Zongertinib
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingPhase 3Boehringer IngelheimNCT07195695Written as Zongertinib
- A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without FoodRecruitingPhase 1Boehringer IngelheimNCT07789028Written as Zongertinib, Formulation A, reference product
- A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.Not yet recruitingPhase 2MedSIRNCT07619066Written as Zongertinib (BI 1810631)
- Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)Active, not recruitingPhase 1Boehringer IngelheimNCT04886804Written as zongertinib
- Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentActive, not recruitingPhase 3Boehringer IngelheimNCT06151574Written as zongertinib
- A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the BloodCompletedPhase 1Boehringer IngelheimNCT07649941Written as Zongertinib
- A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the BloodCompletedPhase 1Boehringer IngelheimNCT06504862Written as Zongertinib
- A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the BodyCompletedPhase 1Boehringer IngelheimNCT06494761Written as zongertinib
- A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the BloodCompletedPhase 1Boehringer IngelheimNCT06028464Written as Zongertinib
- A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the BodyCompletedPhase 1Boehringer IngelheimNCT05879991Written as zongertinib (C-14)
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the BloodCompletedPhase 1Boehringer IngelheimNCT05833139Written as Zongertinib
- A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without FoodCompletedPhase 1Boehringer IngelheimNCT06075277Written as zongertinib
- A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver ProblemsCompletedPhase 1Boehringer IngelheimNCT06692322Written as Zongertinib (BI 1810631)
Given in every arm · 3 — zongertinib is usual care beside what is tested
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as Zongertinib
- Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabRecruitingPhase 2Boehringer IngelheimNCT07486817Written as Zongertinib
- A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the BloodCompletedPhase 1Boehringer IngelheimNCT05380947Written as BI 1810631 - trial formulation 1 (TF1)
Codes
What other systems call zongertinib · ClinicalTrials.gg INT002153
- MeSH (NLM) C000731876zongertinibOne source NLM
- UNII (FDA) DRH7R67UVLZONGERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q135706605zongertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C199022ZongertinibOne source FDA
- DrugBank DB18762One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731876 | zongertinib | One source NLM |
| UNII (FDA) | DRH7R67UVL | ZONGERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q135706605 | zongertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C199022 | Zongertinib | One source FDA |
| DrugBank | DB18762 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.